443642-29-3

443642-29-3 structure

Name: MK-608
Chemical Name: (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
CAS Number: 443642-29-3
Molecular Formula: C₁₂H₁₆N₄O₄
Molecular Weight: 280.280
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2017-06-04 18:32:59
Modify Date: 2024-01-02 14:58:58
MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay[1].

Name	(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
Synonyms	MK-608 Lamevudine (2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 7-deaza-2’-C-methyladenosine 7-Deaza-2'-C-methyladenosine 7DMA 7-(2-C-Methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-

Description	MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay[1].
Related Catalog	Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection
Target	EC50: 0.3 μM (HCV replication)[1]
In Vivo	Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively)[1]. Animal Model: The HCV-infected chimpanzees[1] Dosage: 1 mg/kg Administration: Administered orally; once daily for 37 days Result: Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×106 to 9×106 IU/mL.
References	[1]. Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34.